Tag Archives: Cellectis

Cellectis to Present Updated Clinical Data at ASH 2023; Caribou Still Plans to Share FDA Feedback on CB-010’s Pivotal Trial in 2L LBCL by YE 2023; Cellectis and Caribou Q3 2023 Earnings Summary

On Tuesday, November 7, Cellectis held its Q3 2023 earnings call (press release) highlighting new clinical data presentations from its pipeline programs at ASH 2023. On the same day, Caribou released its Q3 2023 financial results (press release) noting still plans to share the FDA feedback on CB-010’s (allogeneic CD19 CAR-T; PD-1 KO + TCR KO) potential pivotal trial in 2L LBCL by YE 2023 while sharing updated milestones for its other allogeneic cell therapy assets. Below, Celltelligence provides insights on the potential strategies of Cellectis and Caribou for the development of their cell therapy programs, while commenting on their recently closed partnerships with larger companies.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

AstraZeneca and Cellectis Enter into Collaboration to Develop up to 10 Novel Cell and Gene Therapy Candidates Leveraging Cellectis’s Gene Editing Technologies and Manufacturing Capabilities

On Wednesday, November 1, AstraZeneca (press release) and Cellectis (press release) announced they entered into a strategic collaboration and investment agreement for the development of up to 10 novel cell and gene therapy candidate products in areas of high unmet need, including oncology, immunology, and rare diseases. Below, Celltelligence provides insights on the partnership, analyzes Cellectis’s TALEN-based gene-editing platform, and discusses how both companies could benefit from the collaboration.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Cellectis to Provide Updates of All Clinical Programs in 2023; Company to Advance FAP-Targeting UCART Program in Solid Tumors into the Clinic; Precision Actively Seeking Partners to Advance Azer-cel and PBCAR19B; Cellectis’s and Precision’s Q2 2023 Earnings Call Summary

On Friday, August 4, Cellectis held its Q2 2023 earnings call (press release) highlighting anticipated updates for the clinical programs of UCART22 (allogeneic CD22 CAR-T), UCART20x22 (allogeneic CD20xCD22 CAR-T) and UCART123 (allogeneic CD123 CAR-T) later in 2023. On the same day, Precision reported its Q2 2023 earnings call (press release) reiterating the receipt of final Type B meeting minutes from the FDA providing clarity on the potential registrational pathway of its lead asset azer-cel (PBCAR0191; allogeneic CD19 CAR-T), and the active discussions with potential partners for the development of its cell therapy assets. Below, Celltelligence provides insights on Cellectis’s updates of its UCAR-T assets, while discussing Precision’s active search for partnerships and azer-cel’s potential in LBCL.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Promising Preliminary GC007g Efficacy Data in B-ALL Patients that Relapsed Post-Allo-HSCT; Prior CD19-Targeting Treatments Could Affect Tecartus Efficacy in R/R ALL; UCART22 Shows 50% CR in r/r B-ALL Patients Failing Previous CD19 CAR-T Therapy; EHA 2023 Analysis 1

EHA 2023 Analysis 1: Gracell, Gilead (Kite), and Cellectis presented clinical updates from their programs in B-ALL. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Cellectis to Deprioritize its Multiple Myeloma Program; All Ongoing Trials to Include Sanofi’s Alemtuzumab as Lymphodepleting Agent; Cellectis’s Q1 2023 Earnings Call Summary

On Friday, May 5, Cellectis held its Q1 2023 earnings call (press release) highlighting the company’s decision to deprioritize the clinical development of UCARTCS1 (allogeneic CS1 CAR-T) in multiple myeloma to focus on the advancement of the rest of its pipeline. Below, Celltelligence provides insight on Cellectis’s decision to stop investing in its MM program, while discussing the implementation of Sanofi’s alemtuzumab (anti-CD52 mAb) across all its trials.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

CRISPR Tx, Adaptimmune, and Cellectis Report Data in Solid Tumors; AACR 2023 Analysis 1

AACR 2023 Analysis 1: CRISPR Tx, Adaptimmune, and Cellectis presented data on their CAR-T assets for solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Cellectis’s UCART20x22 Trial in NHL Starts Enrollment; Precision’s Azer-cel and PBCAR19B Programs Delayed; Poseida to Provide Further Clinical Updates in 2023; Cellectis, Precision, and Poseida Q4 2022 Earnings Calls Summary

On Thursday, March 9, the following companies released their Q4 and FY 2022 earnings providing clinical updates and financial results:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Poseida, CRISPR Tx, and Cellectis Present Novel Allogeneic CAR-T for Solid Tumors; SITC 2022 Analysis 1

SITC 2022 Analysis 1: Poseida, CRISPR Tx, and Cellectis presented preclinical and clinical updates from their allogeneic cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Updated Results from UCART123 and UCARTCS1 at ASH 2022; UCART20x22 and UCART22 Manufactured In-House; Cellectis’s Q3 2022 Earnings Call Summary

On Friday, November 4, Cellectis held its Q3 2022 earnings call (press release) highlighting that preliminary clinical data from UCART123’s (allogeneic CD123 CAR-T) Ph1 AMELI-01 study in r/r AML and preclinical results from UCARTCS1 (allogeneic CS1 CAR-T) will be presented at ASH 2022 (Dec 10 – 13). Of note, no major clinical updates were provided from UCART20x22 (allogeneic CD20 x CD22 CAR-T) or UCART22 (allogeneic CD22 CAR-T). Below, Celltelligence provides insights on UCART123’s anticipated clinical results, while discussing the progress of other pipeline assets.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Servier Discontinues Partnership with Allogene

On Wednesday, September 21, Allogene reported (SEC Filing) that Servier has discontinued its involvement in the development of allogeneic CD19-directed assets, including Allogene’s most advanced candidates such as ALLO-501, ALLO-501A, and UCART19. Below, Celltelligence provides insights on how the lack of an ex-US licensing partner could affect Allogene’s pipeline development.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.